Estrogens and Parkinson's disease
| Autor: | Amalia C. Kelly, D.R. Session, R. Jewelewicz, M.M. Pearlstone |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
medicine.medical_specialty Parkinson's disease medicine.drug_class Nigrostriatal pathway Disease General Biochemistry Genetics and Molecular Biology Central nervous system disease Dopamine Internal medicine medicine Humans business.industry Parkinsonism Obstetrics and Gynecology Estrogens Parkinson Disease General Medicine medicine.disease nervous system diseases Menopause medicine.anatomical_structure Endocrinology Premenopause Estrogen Extrapyramidal system Female Leuprolide business hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Maturitas. 21:160 |
| ISSN: | 0378-5122 |
| DOI: | 10.1016/0378-5122(95)90004-7 |
| Popis: | There is substantial evidence that estrogens modulate the activity of dopamine in the extrapyramidal system. However, there is conflicting data as to the exact mechanism of estrogen's effects. The majority of clinical reports support an antidopaminergic effect of estrogens on Parkinsonian symptoms. Generally, Parkinsonism worsens with estrogen therapy. We report a case of improvement in Parkinsonian symptoms in a premenopausal patient when placed on leuprolide acetate. The pharmacologic menopause induced by leuprolide acetate leads to a hypoestrogenic state. We hypothesize that the decrease in estrogen improves Parkinson's disease symptoms via the relief of its antidopaminergic effects on the nigrostriatal pathway. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect